retatrutide triple agonist obesity phase 2 trial Eli Lilly's 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide triple agonist gip glp-1

Inflammation First: How GLP-1s Act Independently of Weight Loss A groundbreaking finding in GLP-1 clinical trials is that these compounds can significantly reduce inflammatory markers and improve inflammatory conditions before any substantial changes in body weight or blood glucose levels are observed

Does this help with Menopausal Weight Gain

Why GHK-Cu has shorter stability Most peptides remain stable in reconstituted form for 4-6 weeks refrigerated

Sulphur burps (also called sulphurous burps or rotten egg burps) are an unpleasant side effect experienced by some individuals from GLP-1 injections, such as tirzepatide, (Mounjaro) and semaglutide (Wegovy) and tirzepatide, for weight management

Sleep allows repair processes to work optimally

Tirzepatide and hair loss Tirzepatide provides the most directly comparable data because it was the first dual-agonist to track hair loss in pivotal trials